{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:41:49Z","timestamp":1788309709743,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.autrev.2018.01.016","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T06:01:49Z","timestamp":1525240909000},"page":"660-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis"],"prefix":"10.1016","volume":"17","author":[{"given":"Alina","family":"Casian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish R.","family":"Sangle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"D'Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3 Suppl 82","key":"10.1016\/j.autrev.2018.01.016_bb0005","first-page":"S90","article-title":"Genetics of ANCA-associated vasculitides: HLA and beyond","volume":"32","author":"Alberici","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0010","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.016_bb0015","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.autrev.2014.08.017","article-title":"Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment","volume":"13","author":"Comarmond","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.016_bb0020","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.016_bb0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial Research Group","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.016_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.016_bb0035","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2018.01.016_bb0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/art.20234","article-title":"Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis","volume":"51","author":"Slot","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.016_bb0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.016_bb0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.autrev.2013.11.003","article-title":"Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients","volume":"13","author":"Thai","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.016_bb0055","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3899\/jrheum.130200","article-title":"Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable","volume":"40","author":"Hilhorst","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0060","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","article-title":"Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's clinical occurrence of thrombosis (WeCLOT) study","volume":"142","author":"Merkel","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2018.01.016_bb0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0070","first-page":"223","article-title":"A postgraduate lecture on lupus erythematosus","volume":"4","author":"Payne","year":"1894","journal-title":"Clin J"},{"key":"10.1016\/j.autrev.2018.01.016_bb0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.38956","article-title":"For the French Vasculitis study group. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis data from a French nationwide study of fifty-seven patients","volume":"67","author":"Jachiet","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.016_bb0080","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/ard.2009.127225","article-title":"Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Gaujoux-Viala","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.016_bb0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/BOR.0000000000000126","article-title":"Rheumatoid vasculitis: an update","volume":"27","author":"Makol","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1191\/096120301669779293","article-title":"Antimalarial therapy: a panacea for mild lupus?","volume":"10","author":"D'Cruz","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.016_bb0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.016_bb0100","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3899\/jrheum.120572","article-title":"The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus","volume":"40","author":"Akhavan","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.5","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2018.01.016_bb0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0961203307086503","article-title":"Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival","volume":"17","author":"Siso","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.016_bb0115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1191\/0961203306lu2313oa","article-title":"Hydroxychloroquine use predicts complete renal remission within 12\u202fmonths among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis","volume":"15","author":"Kasitanon","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.016_bb0120","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.autrev.2015.04.010","article-title":"Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?","volume":"14","author":"De Carolis","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.016_bb0125","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.016_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","article-title":"Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA\/Ro antibody associated cardiac manifestations of neonatal lupus","volume":"126","author":"Izmirley","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2018.01.016_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.016_bb0145","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.016_bb0150","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.autrev.2014.12.006","article-title":"Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome","volume":"14","author":"Belizna","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"5744","key":"10.1016\/j.autrev.2018.01.016_bb0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/bmj.1.5744.312","article-title":"Prevention of postoperative deep venous thrombosis and pulmonary embolism","volume":"1","author":"Carter","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.autrev.2018.01.016_bb0160","first-page":"714","article-title":"Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin","volume":"145","author":"Wu","year":"1977","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.autrev.2018.01.016_bb0165","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2106\/00004623-197658070-00003","article-title":"Prevention of venous thromboembolism by administration of hydroxychloroquine. A preliminary report","volume":"58","author":"Chrisman","year":"1976","journal-title":"J Bone Joint Surg Am"},{"issue":"144","key":"10.1016\/j.autrev.2018.01.016_bb0170","first-page":"174","article-title":"Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty","author":"Johnson","year":"1979","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.autrev.2018.01.016_bb0175","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2106\/00004623-197658080-00008","article-title":"Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine","volume":"58","author":"Hansen","year":"1976","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.autrev.2018.01.016_bb0180","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/01.HYP.37.4.1075","article-title":"Vascular stiffness in women with systemic lupus erythematosus","volume":"37","author":"Selzer","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.autrev.2018.01.016_bb0185","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.016_bb0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1196\/annals.1422.003","article-title":"Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment","volume":"1108","author":"Tanay","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2018.01.016_bb0195","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1177\/0961203396005001051","article-title":"Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis","volume":"5","author":"Petri","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.016_bb0200","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1742-7843.2010.00604.x","article-title":"Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus","volume":"107","author":"Bengtsson","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0205","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.20433","article-title":"A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis","volume":"63","author":"Suppiah","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2018.01.016_bb0210","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/art.39070","article-title":"Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis","volume":"67","author":"Feldman","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.016_bb0215","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.autrev.2018.01.016_bb0220","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.2001.02553.x","article-title":"Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors","volume":"112","author":"Lagneaux","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0225","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/CAD.0b013e32832f4e50","article-title":"Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells","volume":"20","author":"Rahim","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.autrev.2018.01.016_bb0230","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.intimp.2015.03.027","article-title":"How are we treating our patients with primary Sj\u00f6gren's syndrome? Analysis of 1120 patients","volume":"27","author":"Gheitasi","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0235","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/ard.57.10.582","article-title":"Long-term effectiveness of antimalarial drugs in rheumatic diseases","volume":"57","author":"Avina-Zubieta","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.016_bb0240","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/art.1780400817","article-title":"Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice","volume":"40","author":"Levy","year":"1997","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0245","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archopht.1982.01030030845024","article-title":"Safety of hydroxychloroquine","volume":"100","author":"Frenkel","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0250","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2018.01.016_bb0255","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1177\/0961203396005001031","article-title":"Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.016_bb0260","first-page":"229","article-title":"Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjogren's syndrome","volume":"11","author":"Mumcu","year":"2013","journal-title":"Oral Health Prev Dent"},{"key":"10.1016\/j.autrev.2018.01.016_bb0265","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.autrev.2015.04.009","article-title":"CRI (Club Rhumatismes et inflammation) and the French Vasculitis study group. ANCA-associated vasculitis in patients with primary Sj\u00f6gren's syndrome: detailed analysis of 7 new cases and systematic literature review","volume":"14","author":"Guellec","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.016_bb0270","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaut.2005.08.004","article-title":"BAFF is elevated in serum of patients with Wegener's granulomatosis","volume":"25","author":"Krumbholz","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2018.01.016_bb0275","first-page":"803","article-title":"Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells","volume":"20","author":"Sperber","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0280","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.autrev.2015.06.008","article-title":"Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides","volume":"14","author":"Dumoitier","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.016_bb0285","doi-asserted-by":"crossref","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","article-title":"Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients","volume":"68","author":"da Silva","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.autrev.2018.01.016_bb0290","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1002\/art.1780401116","article-title":"Induction of interleukin-1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells","volume":"40","author":"de Bandt","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.016_bb0295","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/09629350400003100","article-title":"Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome?","volume":"13","author":"Ohlsson","year":"2004","journal-title":"Mediators Inflamm"},{"issue":"9","key":"10.1016\/j.autrev.2018.01.016_bb0300","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ncprheum0292","article-title":"Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling","volume":"2","author":"Kyburz","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0305","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/187152807783334300","article-title":"TLR7\/9 antagonists as therapeutics for immune-mediated inflammatory disorders","volume":"6","author":"Sun","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.autrev.2018.01.016_bb0310","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2172-9-34","article-title":"CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis","volume":"9","author":"Hurtado","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.10.020","article-title":"Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms","volume":"14","author":"Konstantinov","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.016_bb0320","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/rheumatology\/kes415","article-title":"Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis","volume":"52","author":"Holle","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2018.01.016_bb0325","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2018.01.016_bb0330","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.jaci.2013.02.026","article-title":"Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells","volume":"131","author":"van Loosdregt","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0335","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10157-009-0230-2","article-title":"Analysis of T-cell receptor usage in myeloperoxidase\u2014antineutrophil cytoplasmic antibody-associated renal vasculitis","volume":"14","author":"Hirayama","year":"2010","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0340","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bcp.2013.05.013","article-title":"Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis","volume":"86","author":"Yang","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0345","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.autrev.2015.07.010","article-title":"Emerging role of high mobility group box 1 in ANCA-associated vasculitis","volume":"14","author":"Wang","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.016_bb0350","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0961203309356455","article-title":"Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus","volume":"19","author":"Lesiak","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.01.016_bb0355","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/annrheumdis-2012-201981","article-title":"Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis","volume":"72","author":"Monach","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.016_bb0360","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0037-1613033","article-title":"Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies","volume":"87","author":"Espinola","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2018.01.016_bb0365","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","article-title":"Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers","volume":"112","author":"Rand","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2018.01.016_bb0370","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2018.01.016_bb0375","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.V89.7.2429","article-title":"Apoptotic vascular endothelial cells become procoagulant","volume":"89","author":"Bombeli","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2018.01.016_bb0380","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","author":"The Canadian Hydroxychloroquine Study Group","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.01.016_bb0385","first-page":"485","article-title":"Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients","volume":"61","author":"Le Guennec","year":"1994","journal-title":"Rev Rhum Ed Fr"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2018.01.016_bb0390","first-page":"1972","article-title":"Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis: a double blind randomized controlled trial","volume":"60","author":"Sailler","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.016_bb0395","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10067-013-2245-z","article-title":"ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review","volume":"32","author":"Lenert","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0400","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2133.1982.tb00295.x","article-title":"Urticarial vasculitis: a report of nine cases and review of the literature","volume":"107","author":"Callen","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0405","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/15569520601013269","article-title":"HCQ and UV: recurrent optic disc and retinal vasculitis in a patient with drug-induced urticarial vasculitis","volume":"25","author":"Batio\u011flu","year":"2006","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0410","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/0091-6749(84)90518-9","article-title":"The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine","volume":"73","author":"Lopez","year":"1984","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0415","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/00015550152572985","article-title":"Angiooedema due to acquired deficiency of C1-esterase inhibitor associated with leucocytoclastic vasculitis","volume":"81","author":"Farkas","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2018.01.016_bb0420","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1365-2230.2009.03685.x","article-title":"Systemic vasculitis developing after hydroxychloroquine interruption in a patient with Sj\u00f6gren's syndrome","volume":"35","author":"Okan","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"suppl2","key":"10.1016\/j.autrev.2018.01.016_bb0425","first-page":"159","article-title":"Hydroxychloroquine in ANCA positive and negative vasculitis","volume":"129","author":"Casian","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.autrev.2018.01.016_bb0430","first-page":"524","article-title":"Churg-Strauss syndrome: clinical features and long-term follow-up of 16 patients","volume":"89","author":"Lou","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T08:51:20Z","timestamp":1571302280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218301058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1568997218301058"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.016","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}